Relevant bibliographies by topics / Pigment epithelium-derived factor / Journal articles

Journal articles on the topic 'Pigment epithelium-derived factor'

To see the other types of publications on this topic, follow the link: Pigment epithelium-derived factor.
Author: Grafiati
Published: 4 June 2021
Last updated: 18 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Pigment epithelium-derived factor.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Bell, Christopher. "Pigment Epithelium-Derived Factor." Exercise and Sport Sciences Reviews 39, no. 4 (October 2011): 187–90. http://dx.doi.org/10.1097/jes.0b013e31822673f0.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Shao, Hanshuang, Iris Schvartz, and Shmuel Shaltiel. "Secretion of pigment epithelium-derived factor." European Journal of Biochemistry 270, no. 5 (September 10, 2003): 822–31. http://dx.doi.org/10.1046/j.1432-1033.2003.03374.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Rogers, Morgan E., Iris D. Navarro, Kristin M. Perkumas, Shannon M. Niere, R. Rand Allingham, Craig E. Crosson, and W. Daniel Stamer. "Pigment Epithelium-Derived Factor Decreases Outflow Facility." Investigative Opthalmology & Visual Science 54, no. 10 (October 11, 2013): 6655. http://dx.doi.org/10.1167/iovs.13-12766.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Becerra, S. Patricia, L. Alberto Perez-Mediavilla, John E. Weldon, Silvia Locatelli-Hoops, Preenie Senanayake, Luigi Notari, Vicente Notario, and Joe G. Hollyfield. "Pigment Epithelium-derived Factor Binds to Hyaluronan." Journal of Biological Chemistry 283, no. 48 (September 19, 2008): 33310–20. http://dx.doi.org/10.1074/jbc.m801287200.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Ho, Tsung-Chuan, Yuh-Cheng Yang, Huey-Chuan Cheng, Ai-Ching Wu, Show-Li Chen, and Yeou-Ping Tsao. "Pigment epithelium-derived factor protects retinal pigment epithelium from oxidant-mediated barrier dysfunction." Biochemical and Biophysical Research Communications 342, no. 2 (April 2006): 372–78. http://dx.doi.org/10.1016/j.bbrc.2006.01.164.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Fernandez-Garcia, N. I., O. V. Volpert, and B. Jimenez. "Pigment epithelium-derived factor as a multifunctional antitumor factor." Journal of Molecular Medicine 85, no. 1 (November 15, 2006): 15–22. http://dx.doi.org/10.1007/s00109-006-0111-z.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Yamagishi, Sho-ichi, and Takanori Matsui. "Pigment Epithelium-derived Factor (PEDF) and Cardiometabolic Disorders." Current Pharmaceutical Design 20, no. 14 (May 31, 2014): 2377–86. http://dx.doi.org/10.2174/13816128113199990473.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Ek, Eugene T. H., Crispin R. Dass, and Peter F. M. Choong. "Pigment epithelium-derived factor: a multimodal tumor inhibitor." Molecular Cancer Therapeutics 5, no. 7 (July 2006): 1641–46. http://dx.doi.org/10.1158/1535-7163.mct-06-0107.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Cosgrove, Gregory P., Kevin K. Brown, William P. Schiemann, Amanda E. Serls, Jane E. Parr, Mark W. Geraci, Marvin I. Schwarz, Carlyne D. Cool, and G. Scott Worthen. "Pigment Epithelium–derived Factor in Idiopathic Pulmonary Fibrosis." American Journal of Respiratory and Critical Care Medicine 170, no. 3 (August 2004): 242–51. http://dx.doi.org/10.1164/rccm.200308-1151oc.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Patricia Becerra, S. "Focus on Molecules: Pigment epithelium-derived factor (PEDF)." Experimental Eye Research 82, no. 5 (May 2006): 739–40. http://dx.doi.org/10.1016/j.exer.2005.10.016.

Full text
APA, Harvard, Vancouver, ISO, and other styles
11

Huang, Kuang-Tzu, Chih-Che Lin, Ming-Chao Tsai, Kuang-Den Chen, and King-Wah Chiu. "Pigment epithelium-derived factor in lipid metabolic disorders." Biomedical Journal 41, no. 2 (April 2018): 102–8. http://dx.doi.org/10.1016/j.bj.2018.02.004.

Full text
APA, Harvard, Vancouver, ISO, and other styles
12

Kuntysheva, K. E. "Assessment of angiogenic factors activity variation in the prediction of diabetic retinopathy progression after phacoemulsification." Kazan medical journal 95, no. 2 (April 15, 2014): 284–87. http://dx.doi.org/10.17816/kmj2082.

Full text
Abstract:
Aim. To evaluate the variations of vascular endothelial growth factor and pigment epithelium-derived factor balance as a prognostic factor for diabetic retinopathy progression after phacoemulsification. Methods. The study analyzed 4 samples of tear fluid taken from 2 patients (2 examples per patient). Clinical and functional tests, such as visual acuity test, tonometry, refractometry, visual field test, biomicroscopy, direct ophthalmoscopy, immunoassay, optical coherence tomography, fluorescein angiography, were performed. Clinical and laboratory parameters of homeostasis, including tear concentration of vascular endothelial growth factor and pigment epithelium-derived factor, blood glycosylated hemoglobin level were examined before and after phacoemulsification. Dynamic ophthalmologic control of diabetic retinopathy clinical course was performed. Results. The concentration of pro-angiogenic vascular endothelial growth factor was noted in both cases after the surgery. Hence, in one patient its growth (375 pg/ml before surgery, 467 pg/ml after surgery) exceeded the changes of pigment epithelium-derived factor concentration (2.08 ng/ml before surgery, 1.6 ng/ml after surgery). The progression risk index was estimated as 1.245 for vascular endothelial growth factor and 0.77 for pigment epithelium-derived factor. In second patient, vascular endothelial growth factor also increased after surgery, although, it’s increase (from 335 pg/ml before surgery to 358 pg/ml after surgery) was similar to pigment epithelium-derived factor change (2.15 ng/ml before surgery, 2.02 ng/ml after surgery). The progression risk index in second patient was estimated as 1.07 for vascular endothelial growth factor and 0.94 for pigment epithelium-derived factor. These changes allowed to predict pro-angiogenic potential increase and progression of vascular damage from diabetic retinopathy, in first patient. The second patient had stable balance of pro- and anti-angiogenic factors, allowing to predict a favorable clinical course. Conclusion. The change in vascular endothelial growth factor and pigment epithelium-derived factor ratio over time may be used as a prognostic factor for diabetic retinopathy progression after phacoemulsification.
APA, Harvard, Vancouver, ISO, and other styles
13

Chavan, Sangeeta S., LaQueta K. Hudson, Jian Hua Li, Mahendar Ochani, Yael Harris, Nirav B. Patel, David Katz, Joshua A. Scheinerman, Valentin A. Pavlov, and Kevin J. Tracey. "Identification of Pigment Epithelium-Derived Factor as an Adipocyte-Derived Inflammatory Factor." Molecular Medicine 18, no. 8 (June 14, 2012): 1161–68. http://dx.doi.org/10.2119/molmed.2012.00156.

Full text
APA, Harvard, Vancouver, ISO, and other styles
14

Zhang, Sarah X., Joshua J. Wang, Guoquan Gao, Chunkui Shao, Robert Mott, and Jian‐xing Ma. "Pigment epithelium‐derived factor (PEDF) is an endogenous antiinflammatory factor." FASEB Journal 20, no. 2 (December 20, 2005): 323–25. http://dx.doi.org/10.1096/fj.05-4313fje.

Full text
APA, Harvard, Vancouver, ISO, and other styles
15

Brook, Naomi, Emily Brook, Crispin R. Dass, Arlene Chan, and Arun Dharmarajan. "Pigment Epithelium-Derived Factor and Sex Hormone-Responsive Cancers." Cancers 12, no. 11 (November 23, 2020): 3483. http://dx.doi.org/10.3390/cancers12113483.

Full text
Abstract:
Oestrogens and androgens play important roles in normal and cancerous tissue and have been shown to negatively regulate pigment epithelium-derived factor (PEDF) expression in sex hormone-responsive tumours. PEDF suppresses tumour growth and its downregulation by oestrogen is implicated in tumorigenesis, metastasis, and progression. PEDF expression is reduced in cancerous tissue of the prostate, breast, ovary, and endometrium compared to their normal tissue counterparts, with a link between PEDF downregulation and sex hormone signalling observed in pre-clinical studies. PEDF reduces growth and metastasis of tumour cells by promoting apoptosis, inhibiting angiogenesis, increasing adhesion, and reducing migration. PEDF may also prevent treatment resistance in some cancers by downregulating oestrogen receptor signalling. By interacting with components of the tumour microenvironment, PEDF counteracts the proliferative and immunosuppressive effects of oestrogens, to ultimately reduce tumorigenesis and metastasis. In this review, we focus on sex hormone regulation of PEDF’s anti-tumour action in sex hormone-responsive tumours.
APA, Harvard, Vancouver, ISO, and other styles
16

Wågsäter, Dick, Sture Löfgren, Niklas Zar, Anders Hugander, and Jan Dimberg. "Pigment Epithelium-Derived Factor Expression in Colorectal Cancer Patients." Cancer Investigation 28, no. 8 (May 26, 2010): 872–77. http://dx.doi.org/10.3109/07357901003735675.

Full text
APA, Harvard, Vancouver, ISO, and other styles
17

Miller, Irit, Hadas Bar-Joseph, Luba Nemerovsky, Ido Ben-Ami, and Ruth Shalgi. "Pigment epithelium-derived factor (PEDF) negates hyperandrogenic PCOS features." Journal of Endocrinology 245, no. 2 (May 2020): 291–300. http://dx.doi.org/10.1530/joe-19-0603.

Full text
Abstract:
Polycystic ovary syndrome (PCOS), one of the most common female endocrine disorder, is a prevalent cause of infertility. Hyperandrogenism is a key feature in PCOS and is correlated with increased expression of VEGF and cytokines in the ovaries. We have previously shown that pigment epithelium-derived factor (PEDF), an endogenous protein, presents potent anti-angiogenic and anti-inflammatory activities in the ovary and negates the effects of cytokines and VEGF. Additionally, PEDF plays a role in both pathophysiology and treatment of ovarian-hyperstimulation syndrome (OHSS), frequently seen in PCOS patients. We established hyperandrogenic-PCOS models, both in vivo, using mice exposed prenatally to dihydrotestosterone (DHT) and, in vitro, using human primary granulosa cells (hpGCs) and human granulosa cell line (KGN). In PCOS-induced mice, the mRNA levels of I l-6, V egf and Amh were higher than those of control; yet, treatment with rPEDF decreased these levels. Moreover, treating OHSS-induced PCOS-mice with rPEDF alleviated all OHSS symptoms. Stimulation of hpGCs with DHT resulted in downregulation of PEDF mRNA expression, concomitantly with a significant increase in IL-6 and IL-8 mRNAs expression. However, co-stimulation of DHT with rPEDF attenuated the increase in cytokines expression. The anti-inflammatory effect of PEDF was found to be mediated via PPARγ pathway. Our findings suggest that rPEDF treatment may normalize the ovarian angiogenic-inflammatory imbalance, induced by PCOS-associated hyperandrogenism. Moreover, the therapeutic potency of PEDF in preventing OHSS symptomes offers a rationale for using PEDF as novel physiological treatment for PCOS sequels.
APA, Harvard, Vancouver, ISO, and other styles
18

Yamagishi, Sho-ichi, Yoshinori Koga, Ami Sotokawauchi, Naoki Hashizume, Suguru Fukahori, Takanori Matsui, and Minoru Yagi. "Therapeutic Potential of Pigment Epithelium-derived Factor in Cancer." Current Pharmaceutical Design 25, no. 3 (May 30, 2019): 313–24. http://dx.doi.org/10.2174/1381612825666190319112106.

Full text
Abstract:
Pigment epithelium-derived factor (PEDF) is one of the serine protease inhibitors with multifunctional properties, which is produced by various types of organs and tissues. There is an accumulating body of evidence that PEDF plays an important role in the maintenance of tissue homeostasis. Indeed, PEDF not only works as an endogenous inhibitor of angiogenesis, but also suppresses oxidative stress, inflammatory and thrombotic reactions in cell culture systems, animal models, and humans. Furthermore, we, along with others, have found that PEDF inhibits proliferation of, and induces apoptotic cell death in, numerous kinds of tumors. In addition, circulating as well as tumor expression levels of PEDF have been inversely associated with tumor growth and metastasis. These observations suggest that supplementation of PEDF proteins and/or enhancement of endogenous PEDF expression could be a novel therapeutic strategy for the treatment of cancer. Therefore, in this paper, we review the effects of PEDF on diverse types of cancer, and discuss its therapeutic perspectives.
APA, Harvard, Vancouver, ISO, and other styles
19

Ogata, Nahoko, Joyce Tombran-Tink, Nobuo Jo, David Mrazek, and Miyo Matsumura. "Upregulation of pigment epithelium-derived factor after laser photocoagulation." American Journal of Ophthalmology 132, no. 3 (September 2001): 427–29. http://dx.doi.org/10.1016/s0002-9394(01)01021-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
20

Akpinar, Muhammet Yener, Evrim Kahramanoglu Aksoy, Ferdane Pirincci Sapmaz, Ozlem Ceylan Dogan, Metin Uzman, and Yasar Nazligul. "Pigment Epithelium-Derived Factor Affects Angiogenesis in Celiac Disease." Medical Principles and Practice 28, no. 3 (2019): 236–41. http://dx.doi.org/10.1159/000497612.

Full text
Abstract:
Objective: Recent studies have demonstrated that angiogenesis is impaired in patients with celiac disease (CD). In this study, we evaluated the levels of the novel antiangiogenic factor pigment epithelium-derived factor (PEDF) in CD patients. Methods: Eighty-four patients were included in the study; 71 patients with CD and 13 healthy controls. In the CD patient cohort, there were 21 newly diagnosed patients, 19 with adherence to a gluten-free diet and 31 practicing no adherence to this diet. The PEDF levels were measured using enzyme-linked immunosorbent assays. Results: The data revealed that celiac patients had higher levels of PEDF than did healthy controls. PEDF levels were not significantly different among the three CD groups. Additionally, the PEDF levels were not correlated with tissue transglutaminase IgA or IgG. Conclusions: Our data indicate that PEDF levels are significantly higher in CD patients than those in the healthy controls. This result suggests that PEDF negatively affects angiogenesis in CD. Although we did not observe any differences of PEDF levels among celiac patients, additional studies including more patients could clarify this issue.
APA, Harvard, Vancouver, ISO, and other styles
21

Sakurai, Shinichi, Nobuo Ohta, Masaru Aoyagi, and Sanai Sato. "Effect of Pigment Epithelium Derived Factor on Microvascular Cells." Otolaryngology–Head and Neck Surgery 131, no. 2 (August 2004): P287. http://dx.doi.org/10.1016/j.otohns.2004.06.617.

Full text
APA, Harvard, Vancouver, ISO, and other styles
22

Dong, Yu-hao, Zi-quan Li, Yi Sun, Le Zhuang, Yu-kun Wang, and Qing Sun. "Downregulation of pigment epithelium-derived factor in condyloma acuminatum." Journal of International Medical Research 41, no. 2 (March 14, 2013): 365–70. http://dx.doi.org/10.1177/0300060513476584.

Full text
APA, Harvard, Vancouver, ISO, and other styles
23

Mori, Keisuke, Elia Duh, Peter Gehlbach, Akira Ando, Kyoichi Takahashi, Joel Pearlman, Keiko Mori, et al. "Pigment epithelium-derived factor inhibits retinal and choroidal neovascularization." Journal of Cellular Physiology 188, no. 2 (2001): 253–63. http://dx.doi.org/10.1002/jcp.1114.

Full text
APA, Harvard, Vancouver, ISO, and other styles
24

Dawson, D. W. "Pigment Epithelium-Derived Factor: A Potent Inhibitor of Angiogenesis." Science 285, no. 5425 (July 9, 1999): 245–48. http://dx.doi.org/10.1126/science.285.5425.245.

Full text
APA, Harvard, Vancouver, ISO, and other styles
25

Goldberg, Keren, Hadas Bar-Joseph, Hadas Grossman, Noa Hasky, Shiri Uri-Belapolsky, Salomon M. Stemmer, Dana Chuderland, Ruth Shalgi, and Irit Ben-Aharon. "Pigment Epithelium–Derived Factor Alleviates Tamoxifen-Induced Endometrial Hyperplasia." Molecular Cancer Therapeutics 14, no. 12 (October 8, 2015): 2840–49. http://dx.doi.org/10.1158/1535-7163.mct-15-0523.

Full text
APA, Harvard, Vancouver, ISO, and other styles
26

Becerra, S. Patricia, Crispin R. Dass, Takeshi Yabe, and Susan E. Crawford. "Pigment Epithelium-Derived Factor: Chemistry, Structure, Biology, and Applications." Journal of Biomedicine and Biotechnology 2012 (2012): 1–2. http://dx.doi.org/10.1155/2012/830975.

Full text
APA, Harvard, Vancouver, ISO, and other styles
27

Becerra, S. Patricia, Alessandra Sagasti, Patricia Spinella, and Vicente Notario. "Pigment Epithelium-derived Factor Behaves Like a Noninhibitory Serpin." Journal of Biological Chemistry 270, no. 43 (October 1995): 25992–99. http://dx.doi.org/10.1074/jbc.270.43.25992.

Full text
APA, Harvard, Vancouver, ISO, and other styles
28

Zhang, Tao, Ming Guan, and Yuan Lu. "Production of active pigment epithelium-derived factor inE. coli." Biotechnology Letters 27, no. 6 (March 2005): 403–7. http://dx.doi.org/10.1007/s10529-005-1549-8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
29

Minkevich, Natalya I., Ludmilla A. Morozova-Roche, Elena N. Iomdina, Tatiana V. Rakitina, Anna P. Bogachuk, Dmitry L. Kakuev, Evgeniya V. Smirnova, Igor I. Babichenko, and Valery M. Lipkin. "Abnormal pigment epithelium-derived factor processing in progressive myopia." Experimental Eye Research 152 (November 2016): 1–9. http://dx.doi.org/10.1016/j.exer.2016.08.017.

Full text
APA, Harvard, Vancouver, ISO, and other styles
30

Dai, Zhiyu, Ti Zhou, Cen Li, Weiwei Qi, Yuling Mao, Juling Lu, Yachao Yao, et al. "Intracellular pigment epithelium-derived factor contributes to triglyceride degradation." International Journal of Biochemistry & Cell Biology 45, no. 9 (September 2013): 2076–86. http://dx.doi.org/10.1016/j.biocel.2013.07.008.

Full text
APA, Harvard, Vancouver, ISO, and other styles
31

Chuderland, Dana, Ido Ben-Ami, Hadas Bar-Joseph, and Ruth Shalgi. "Role of pigment epithelium-derived factor in the reproductive system." REPRODUCTION 148, no. 4 (October 2014): R53—R61. http://dx.doi.org/10.1530/rep-14-0251.

Full text
Abstract:
The physiological function of the female reproductive organs is hormonally controlled. In each cycle, the reproductive organs undergo tissue modifications that are accompanied by formation and destruction of blood vessels. Proper angiogenesis requires an accurate balance between stimulatory and inhibitory signals, provided by pro- and anti-angiogenic factors. As with many other tissues, vascular endothelial growth factor (VEGF) appears to be one of the major pro-angiogenic factors in the female reproductive organs. Pigment epithelium-derived factor (PEDF) is a non-inhibitory member of the serine protease inhibitors (serpin) superfamily, possessing potent physiologic anti-angiogenic activity that negates VEGF activity. The role of PEDF in decreasing abnormal neovascularization by exerting its anti-angiogenic effect that inhibits pro-angiogenic factors, including VEGF, has been investigated mainly in the eye and in cancer. This review summarizes the function of PEDF in the reproductive system, showing its hormonal regulation and its anti-angiogenic activity. Furthermore, some pathologies of the female reproductive organs, including endometriosis, ovarian hyperstimulation syndrome, polycystic ovary syndrome, and others, are associated with a faulty angiogenic process. This review illuminates the role of PEDF in their pathogenesis and treatment. Collectively, we can conclude that although PEDF seems to play an essential role in the physiology and pathophysiology of the reproductive system, its full role and mechanism of action still need to be elucidated.
APA, Harvard, Vancouver, ISO, and other styles
32

Hattenbach, Lars-Olof, Karl-Friedrich Beck, Josef Pfeilschifter, Frank Koch, Christian Ohrloff, and Wolfgang Schacke. "Pigment-Epithelium-Derived Factor Is Upregulated in Photocoagulated Human Retinal Pigment Epithelial Cells." Ophthalmic Research 37, no. 6 (2005): 341–46. http://dx.doi.org/10.1159/000088263.

Full text
APA, Harvard, Vancouver, ISO, and other styles
33

Patricia Becerra, S., Robert N. Fariss, Yan Q. Wu, Luis M. Montuenga, Paul Wong, and Bruce A. Pfeffer. "Pigment epithelium-derived factor in the monkey retinal pigment epithelium and interphotoreceptor matrix: apical secretion and distribution." Experimental Eye Research 78, no. 2 (February 2004): 223–34. http://dx.doi.org/10.1016/j.exer.2003.10.013.

Full text
APA, Harvard, Vancouver, ISO, and other styles
34

Abdiu, Oran, and Gysbert Van Setten. "Possible Role of Pigment-epithelium-derived Factor in Corneal Angiogenesis." European Ophthalmic Review 03, no. 01 (2009): 64. http://dx.doi.org/10.17925/eor.2009.03.01.64.

Full text
Abstract:
The detection of pigment-epithelium-derived factor (PEDF) in corneal tissue has allowed greater understanding of the avascularity of corneal tissue. The ability of the cornea to maintain the avascular nature of this tissue, also referred to as the angiogenic privilege of the cornea, could be partly attributed to the presence of this factor. This privilege is severely impaired by various diseases of the ocular surface associated with inflammation and infection that are often followed by neovascularisation, which compromises the transparency of the cornea and results in visual impairment. The rapidly increasing insights into the basic mechanisms controlling neovascularisation, i.e. balance of growth factor activation and enzymatic activity, has most recently led to the development of large-scale use of specific antiangiogenic agents in the treatment of neovascular age-related macular degeneration (AMD). Focusing on the effects of vascular endothelial growth factor (VEGF), the use of such agents, including bevacizumab (Avastin®), a humanised anti-VEGF monoclonal antibody originally used in the treatment of metastatic colorectal cancer, has been investigated in corneal angiogenesis. PEDF is only one of the many factors involved in ocular angiogenesis. However, although it is only a small protein, it has strong antiangiogenic actions that are expressed in the retinal pigment epithelial (RPE) layer, as well as in other parts of the eye. There are specific characteristics that could designate a special role for PEDF in the regulation of avascularity in the eye. In this article, we focus on corneal angiogenesis and highlight the special features of this somewhat unexplored cytokine, outlining the current knowledge and possible role of PEDF in corneal neovascularisation.
APA, Harvard, Vancouver, ISO, and other styles
35

Ablonczy, Zsolt, Annamalai Prakasam, James Fant, Abdul Fauq, Craig Crosson, and Kumar Sambamurti. "Pigment Epithelium-derived Factor Maintains Retinal Pigment Epithelium Function by Inhibiting Vascular Endothelial Growth Factor-R2 Signaling through γ-Secretase." Journal of Biological Chemistry 284, no. 44 (September 1, 2009): 30177–86. http://dx.doi.org/10.1074/jbc.m109.032391.

Full text
APA, Harvard, Vancouver, ISO, and other styles
36

Terzi, Menderes Yusuf, Pablo Casalis, Veronika Lang, Marietta Zille, Elisabeth Bründl, Eva-Maria Störr, Alexander Brawanski, Peter Vajkoczy, Ulrich Thomale, and Ana Luisa Piña. "Effects of pigment epithelium-derived factor on traumatic brain injury." Restorative Neurology and Neuroscience 33, no. 1 (2015): 81–93. http://dx.doi.org/10.3233/rnn-140417.

Full text
APA, Harvard, Vancouver, ISO, and other styles
37

Perez-Mediavilla, L. Alberto, Christina Chew, Peter A. Campochiaro, Robert W. Nickells, Vicente Notario, Donald J. Zack, and S. Patricia Becerra. "Sequence and expression analysis of bovine pigment epithelium-derived factor." Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression 1398, no. 2 (June 1998): 203–14. http://dx.doi.org/10.1016/s0167-4781(98)00055-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
38

Kim, Jeong-A., Misuk Yang, Young Hoon Park, Youngrok Park, and Jae-Yong Kwak. "Pigment Epithelium-Derived Factor Promotes the Angiogenic Activity of VEGF." Blood 132, Supplement 1 (November 29, 2018): 3687. http://dx.doi.org/10.1182/blood-2018-99-117420.

Full text
Abstract:
Abstract Introduction: We successfully identified a subset of CD11b+ monocytes expressing CX3CR1, the only receptor of fractalkine (Fkn; CX3CL1), in G-CSF mobilized peripheral blood stem cell collection (PBSC). We found that Fkn-treated CD11b+CX3CR1+ monocytes express pigment epithelium-derived factor (PEDF) once Fkn activates Fkn/CX3CR1 signaling. PEDF is a glycoprotein, which belongs to the serpin family and involves various physiologic processes such as angiogenesis, cell proliferation, and survival. In this study, we investigate the role of PEDF and its mechanism of action in promoting angiogenesis. Materials andmethods: To mobilize mononuclear cells (MNCs) including CD11b+CX3CR1+ monocytes into peripheral blood (PB), heathy donors were subcutaneously injected with G-CSF (10μg/kg) for 5 days. Apheresis MNCs were collected from donor PB using a COBE spectra cell separator (COBE, Lakewood, CO) 5 days after daily G-CSF injection. Then, CD11b+CX3CR1+ cells were isolated with a MoFlo™ XDP Cell Sorter (Beckman Coulter, Brea, CA). Human umbilical vein endothelial cells (HUVECs) were isolated from human cords and cultured at 37 °C in 5% CO2 on top of collagen in four different settings: (1) untreated (HUVECs alone) (2) VEGF (1ng/mL) treated HUVECs; (3) PEDF (3,30 and 300 ng/mL) treated HUVECs; (4) VEGF (1ng/mL)+PEDF (3,30 and 300 ng/mL) treated HUVECs. To assess dose-dependency, PEDF was administered at different dosages (0, 3, 30 and 300 ng/mL) for 7 days in either the presence or absence of VEGF (1ng/mL). HUVEC growth areas were measured by image J. Results: CD11b+CX3CR1+ monocytes were found at 19.6±3.58% of total MNCs in human G-CSF mobilized PBSC. Fractalkine treatment (50ng/mL for 30 minutes) of these monocytes promoted endothelial cell proliferation of HUVECs and increased PEDF expression according to the angiogenic protein array results. Administration of PEDF inhibitor significantly decreased HUVEC proliferation and vascular structure formation compared to the control group (p <0.001). We further investigated pro-angiogenic effects of PEDF on HUVEC proliferation. In PEDF (3,30 and 300 ng/mL) treated HUVECs, PEDF itself has minimal effect on HUVEC proliferation. However, EC sprouting at the edge of vessel-like structures was greater in the 3 and 30 ng/mL. Interestingly, there was no EC sprouting with 300 ng/mL PEDF. PEDF (3 and 30 ng/mL) itself showed little effect on HUVEC proliferation. However, co-culturing with VEGF (1ng/mL) and low PEDF concentrations (3 and 30 ng/mL) significantly increased EC proliferation (EC proliferation area (mm2), 1.7±0.4 (VEGF only) vs 3.0±0.6 (VEGF+3 ng/mL PEDF) and 2.5±1.1 (VEGF+30 ng/mL PEDF); p=0.002 and 0.048, respectively). Higher concentration of PEDF did not induced EC proliferation even in the presence VEGF (1.7±0.4 (VEGF only) vs 1.5±0.9 (VEGF+300 ng/mL PEDF); p=0.192). The results suggest that low concentrations of PEDF (3 and 30 ng/mL) has no effect on HUVEC proliferation, but has a potent effect on HUVEC migration regardless of VEGF activity. PEDF is not pro-angiogenic by itself, but can markedly enhance HUVEC proliferation in PEDF (3 and 30 ng/mL) treated HUVECs with VEGF. Conclusion: Fractalkine-treated CD11b+CX3CR1+ monocytes promote angiogenesis by increasing PEDF expression, which acts as a pro-angiogenic factor only under conditions where VEGF is present. Disclosures No relevant conflicts of interest to declare.
APA, Harvard, Vancouver, ISO, and other styles
39

Perruccio, Elizabeth M., Laura Leigh S. Rowlette, Núria Comes, Silvia Locatelli-Hoops, Luigi Notari, S. Patricia Becerra, and Teresa Borrás. "Dexamethasone Increases Pigment Epithelium-Derived Factor in Perfused Human Eyes." Current Eye Research 33, no. 5-6 (January 2008): 507–15. http://dx.doi.org/10.1080/02713680802110208.

Full text
APA, Harvard, Vancouver, ISO, and other styles
40

Abdiu, O., and G. Van Setten. "Antiangiogenic Activity in Tears: Presence of Pigment-Epithelium-Derived Factor." Ophthalmic Research 40, no. 1 (November 20, 2007): 16–18. http://dx.doi.org/10.1159/000111153.

Full text
APA, Harvard, Vancouver, ISO, and other styles
41

Feher, Janos, Illes Kovacs, Elena Pacella, Sandor Keresz, Natascia Spagnardi, and Corrado Balacco Gabrieli. "Pigment Epithelium–Derived Factor (PEDF) Attenuated Capsaicin-Induced Neurotrophic Keratouveitis." Investigative Opthalmology & Visual Science 50, no. 11 (November 1, 2009): 5173. http://dx.doi.org/10.1167/iovs.08-1852.

Full text
APA, Harvard, Vancouver, ISO, and other styles
42

MASER, RAELENE E., JAMES LENHARD, RYAN POHLIG, and P. BABU BALAGOPAL. "Circulating Pigment Epithelium-Derived–Factor Levels—Hyperglycemia vs. Insulin Resistance." Diabetes 67, Supplement 1 (May 2018): 1938—P. http://dx.doi.org/10.2337/db18-1938-p.

Full text
APA, Harvard, Vancouver, ISO, and other styles
43

Abe, Riichiro, Yasuyuki Fujita, Sho-ichi Yamagishi, and Hiroshi Shimizu. "Pigment Epithelium-Derived Factor Prevents Melanoma Growth via Angiogenesis Inhibition." Current Pharmaceutical Design 14, no. 36 (December 1, 2008): 3802–9. http://dx.doi.org/10.2174/138161208786898626.

Full text
APA, Harvard, Vancouver, ISO, and other styles
44

Conti, Antonio, Piero Ricchiuto, Sandro Iannaccone, Barbara Sferrazza, Angela Cattaneo, Angela Bachi, Angelo Reggiani, Massimiliano Beltramo, and Massimo Alessio. "Pigment epithelium-derived factor is differentially expressed in peripheral neuropathies." PROTEOMICS 5, no. 17 (September 30, 2005): 4558–67. http://dx.doi.org/10.1002/pmic.200402088.

Full text
APA, Harvard, Vancouver, ISO, and other styles
45

Kang, Hee Joon, Hyo-Hyun Park, Sung Won Chae, Soon Jae Hwang, Sang Hag Lee, Seung Hoon Lee, and Heung-Man Lee. "Increased Expression of Pigment Epithelium–Derived Factor in Allergic Rhinitis." Archives of Otolaryngology–Head & Neck Surgery 134, no. 10 (October 20, 2008): 1094. http://dx.doi.org/10.1001/archotol.134.10.1094.

Full text
APA, Harvard, Vancouver, ISO, and other styles
46

Matsumoto, Kojiro, Hiroki Ishikawa, Daisuke Nishimura, Keisuke Hamasaki, Kazuhiko Nakao, and Katsumi Eguchi. "Antiangiogenic property of pigment epithelium-derived factor in hepatocellular carcinoma." Hepatology 40, no. 1 (2004): 252–59. http://dx.doi.org/10.1002/hep.20259.

Full text
APA, Harvard, Vancouver, ISO, and other styles
47

Guan, M. "Loss of pigment epithelium derived factor expression in glioma progression." Journal of Clinical Pathology 56, no. 4 (April 1, 2003): 277–82. http://dx.doi.org/10.1136/jcp.56.4.277.

Full text
APA, Harvard, Vancouver, ISO, and other styles
48

Li, C. M., W. Li, X. Y. Man, Z. G. Liu, and M. Zheng. "Expression of pigment epithelium-derived factor in human cutaneous appendages." Clinical and Experimental Dermatology 38, no. 6 (May 16, 2013): 652–58. http://dx.doi.org/10.1111/ced.12066.

Full text
APA, Harvard, Vancouver, ISO, and other styles
49

Bar-Joseph, Hadas, Ido Ben-Ami, Raphael Ron-El, Ruth Shalgi, and Dana Chuderland. "Pigment epithelium–derived factor exerts antioxidative effects in granulosa cells." Fertility and Sterility 102, no. 3 (September 2014): 891–98. http://dx.doi.org/10.1016/j.fertnstert.2014.06.012.

Full text
APA, Harvard, Vancouver, ISO, and other styles
50

Gleich, Otto, and Ana Luisa Piña. "Protein expression of pigment-epithelium-derived factor in rat cochlea." Cell and Tissue Research 332, no. 3 (April 17, 2008): 565–71. http://dx.doi.org/10.1007/s00441-008-0608-6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the bibliographies on the topic 'Pigment epithelium-derived factor' for other source types:
Dissertations / Theses
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography